S1226
Asthma
SolAeroMed Inc.Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Asthma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Budesonide New York City Health and Hospitals Corporation | Phase 4 | BBB |
SALMETEROL Mundipharma (China) Pharmaceutical Co. Ltd | Phase 4 | BBB |
Flixotide GlaxoSmithKline | Phase 4 | BBB |
Montelukast Kafrelsheikh University | Phase 4 | BBB |
Mirabegron Kafrelsheikh University | Phase 4 | BB |
View all 48 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →